Inhaler therapy in adult patients with asthma and COPD: Dry powder or aerosol?;Inhalatiemedicatie bij volwassenen met obstructieve longaandoeningen: Poeder of aerosol?

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 24, 1998, Pages 1369-1374

  Dekhuijzen, P N R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; SALBUTAMOL; TERBUTALINE;

AEROSOL; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; REVIEW;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; FEMALE; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; POWDERS; RESPIRATORY MECHANICS;

EID: 0032513953     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Ross DL, Schultz RK. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. J Aer Med 1996;9:215-26.
2. Hindle M, Byron PR. Dose emissions from marketed dry powder inhalers. Int J Pharmaceut 1995;116:169-77.
3. June D. Achieving the change: challenges and successes in the formulation of CFC-free MDI's. Eur Respir Rev 1997;7:32-4.
4. Richards R, Saunders M. Need for a comparative performance standard for dry powder inhalers. Thorax 1993;48:1186-7.
5. Engel T, Heinig JH, Madsen F, Nikander K. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler). Eur Respir J 1990;3:1037-41.
6. Newman SP, Moren F, Trofast E, Talaee N, Clarke SW. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharmaceut 1991;74:209-13.
7. Pedersen S. How to use a rotahaler. Arch Dis Child 1986;61:11-4.
8. Adcock IM, Gilbev T, Gelder CM, Chung KF, Barnes PJ. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 1996;154(3 Pt 1):771-82.
9. Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue inflammation in asthma Am J Respir Crit Care Med 1996; 154:1505-10.
10. Selroos O, Pietinalho A, Riska H Delivery devices for inhaled asthma medication. Clin Immunother 1996;6:273-99
11. Zanen P, Go LT, Lammers JW. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 1996;51:977-80.
12. Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991;46:712-6.
13. Barry PW, O'Callaghan C. Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range. Eur Respir J 1994;7:1707-9.
14. Borgstrom L, Bondesson E, Moren F, Trofasi E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994;7:69-73
15. Farr S, Rowe A, Rubsamen R, Taylor G. Optimisation of aerosol inhalation from metered-dose inhalers by use of a novel microprocessor-controlled device. Pharm Res 1994;11:158.